Table 3.
The SARS-CoV-2 in EPS and its relevance to nasopharyngeal RNA and serum immunoglobins.
| Patient No. | SARS-CoV-2 RNA in urine pre-palpation | SARS-CoV-2 RNA in EPS post-palpation | Nasopharyngeal SARS-CoV-2 RNA within 3 days of prostate palpation | Serum SARS-CoV-2 IgM | Serum SARS-CoV-2 IgG | The interval (days)* |
|---|---|---|---|---|---|---|
| 1 | Negative | Negative | Positive | Positive | Positive | NA |
| 2 | Negative | Negative | Positive | Positive | Positive | NA |
| 3 | Negative | Negative | Positive | Positive# | NA | |
| 4 | Negative | Negative | Negative | Negative | Positive | 23 |
| 5 | Negative | Negative | Negative | Negative | Positive | 29 |
| 6 | Negative | Negative | Negative | Negative | Positive | 14 |
| 7 | Negative | Negative | Negative | Negative | Positive | 3 |
| 8 | Negative | Negative | Negative | Negative | Positive | 18 |
| 9 | Negative | Negative | Negative | Negative | Positive | 8 |
| 10 | Negative | Negative | Negative | Positive# | 20 | |
*The interval between the first negative nasopharyngeal SARS-CoV-2 RNA test and the day that EPS was taken.
# Immunoglobin was detected unspecificly regardless of IgM or IgG because of the shortage for specific testing kits.
EPS: expressed prostatic secretion.
NA: not applicable.